7
|
Regev K, Healy BC, Paul A, Diaz-Cruz C, Mazzola MA, Raheja R, Glanz BI, Kivisäkk P, Chitnis T, Jagodic M, Piehl F, Olsson T, Khademi M, Hauser S, Oksenberg J, Khoury SJ, Weiner HL, Gandhi R. Identification of MS-specific serum miRNAs in an international multicenter study. NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION 2018; 5:e491. [PMID: 30175165 PMCID: PMC6117192 DOI: 10.1212/nxi.0000000000000491] [Citation(s) in RCA: 55] [Impact Index Per Article: 9.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/13/2018] [Accepted: 06/22/2018] [Indexed: 12/21/2022]
Abstract
Objective To identify circulating microRNAs (miRNAs) linked to disease, disease stage, and disability in MS across cohorts. Methods Samples were obtained from the Comprehensive Longitudinal Investigation of Multiple Sclerosis (CLIMB, Boston, MA), EPIC (San Francisco, CA), AMIR (Beirut, Lebanon) as part of the SUMMIT consortium, and Stockholm Prospective Assessment of Multiple Sclerosis (Stockholm, Sweden) cohorts. Serum miRNA expression was measured using locked nucleic acid–based quantitative PCR. Four groups were compared: (1) MS vs healthy control (HC), (2) relapsing-remitting (RR) vs HC, (3) secondary progressive (SP) vs HC, and (4) RR vs SP. A Wilcoxon rank-sum test was used for the comparisons. The association between each miRNA and the Expanded Disability Status Scale (EDSS) score was assessed using the Spearman correlation coefficient. For each comparison, the p values were corrected for multiple comparisons using the approach of Benjamini and Hochberg to control the false discovery rate. Results In the CLIMB cohort, 5 miRNAs (hsa-miR-484, hsa-miR-140-5p, hsa-miR-320a, hsa-miR-486-5p, and hsa-miR-320c) showed a significant difference between patients with MS and healthy individuals; among these, miR-484 remained significant after accounting for multiple comparisons (p = 0.01). When comparing RRMS with HCs, hsa-miR-484 showed a significant difference (p = 0.004) between the groups after accounting for multiple group comparisons. When SP and HC were compared, 6 miRNAs (hsa-miR-484, hsa-miR-140-5p, hsa-miR-142-5p, hsa-miR-320a, hsa-miR-320b, and hsa-miR-320c) remained significantly different after accounting for multiple comparisons. Disability correlation analysis with miRNA provided 4 miRNAs (hsa-miR-320a, hsa-miR-337-3p, hsa-miR-199a-5p, and hsa-miR-142-5p) that correlated with the EDSS during the internal reproducibility phase. Among these, hsa-miR-337-3p was the most statistically significant miRNA that negatively correlated with the EDSS in three of the MS cohorts tested. Conclusions These findings further confirm the use of circulating serum miRNAs as biomarkers to diagnose and monitor disease status in MS. Classification of evidence This study provides Class III evidence that levels of circulating miRNAs identify patients with MS.
Collapse
Affiliation(s)
- Keren Regev
- Partners Multiple Sclerosis Center (K.R., B.C.H., A.P., M.A.M., R.R., P.K., T.C., H.L.W., R.G.), Brigham and Women's Hospital; Department of Neurology, Harvard Medical School (B.C.H., C.D.-C., B.I.G., T.C., H.L.W, R.G.), Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital; Biostatistics Center (B.C.H.); Massachusetts General Hospital, Boston, MA; Department of Clinical Neuroscience, Neuroimmunology Unit (M.J., F.P., T.O., M.K.), Karolinska Institute, Stockholm, Sweden; Department of Neurology (S.H., J.O.), School of Medicine, University of California, San Francisco; and Nehme and Therese Tohme Multiple Sclerosis Center (S.J.K.), Faculty of Medicine, American University of Beirut Medical Center, Lebanon
| | - Brian C Healy
- Partners Multiple Sclerosis Center (K.R., B.C.H., A.P., M.A.M., R.R., P.K., T.C., H.L.W., R.G.), Brigham and Women's Hospital; Department of Neurology, Harvard Medical School (B.C.H., C.D.-C., B.I.G., T.C., H.L.W, R.G.), Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital; Biostatistics Center (B.C.H.); Massachusetts General Hospital, Boston, MA; Department of Clinical Neuroscience, Neuroimmunology Unit (M.J., F.P., T.O., M.K.), Karolinska Institute, Stockholm, Sweden; Department of Neurology (S.H., J.O.), School of Medicine, University of California, San Francisco; and Nehme and Therese Tohme Multiple Sclerosis Center (S.J.K.), Faculty of Medicine, American University of Beirut Medical Center, Lebanon
| | - Anu Paul
- Partners Multiple Sclerosis Center (K.R., B.C.H., A.P., M.A.M., R.R., P.K., T.C., H.L.W., R.G.), Brigham and Women's Hospital; Department of Neurology, Harvard Medical School (B.C.H., C.D.-C., B.I.G., T.C., H.L.W, R.G.), Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital; Biostatistics Center (B.C.H.); Massachusetts General Hospital, Boston, MA; Department of Clinical Neuroscience, Neuroimmunology Unit (M.J., F.P., T.O., M.K.), Karolinska Institute, Stockholm, Sweden; Department of Neurology (S.H., J.O.), School of Medicine, University of California, San Francisco; and Nehme and Therese Tohme Multiple Sclerosis Center (S.J.K.), Faculty of Medicine, American University of Beirut Medical Center, Lebanon
| | - Camilo Diaz-Cruz
- Partners Multiple Sclerosis Center (K.R., B.C.H., A.P., M.A.M., R.R., P.K., T.C., H.L.W., R.G.), Brigham and Women's Hospital; Department of Neurology, Harvard Medical School (B.C.H., C.D.-C., B.I.G., T.C., H.L.W, R.G.), Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital; Biostatistics Center (B.C.H.); Massachusetts General Hospital, Boston, MA; Department of Clinical Neuroscience, Neuroimmunology Unit (M.J., F.P., T.O., M.K.), Karolinska Institute, Stockholm, Sweden; Department of Neurology (S.H., J.O.), School of Medicine, University of California, San Francisco; and Nehme and Therese Tohme Multiple Sclerosis Center (S.J.K.), Faculty of Medicine, American University of Beirut Medical Center, Lebanon
| | - Maria Antonietta Mazzola
- Partners Multiple Sclerosis Center (K.R., B.C.H., A.P., M.A.M., R.R., P.K., T.C., H.L.W., R.G.), Brigham and Women's Hospital; Department of Neurology, Harvard Medical School (B.C.H., C.D.-C., B.I.G., T.C., H.L.W, R.G.), Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital; Biostatistics Center (B.C.H.); Massachusetts General Hospital, Boston, MA; Department of Clinical Neuroscience, Neuroimmunology Unit (M.J., F.P., T.O., M.K.), Karolinska Institute, Stockholm, Sweden; Department of Neurology (S.H., J.O.), School of Medicine, University of California, San Francisco; and Nehme and Therese Tohme Multiple Sclerosis Center (S.J.K.), Faculty of Medicine, American University of Beirut Medical Center, Lebanon
| | - Radhika Raheja
- Partners Multiple Sclerosis Center (K.R., B.C.H., A.P., M.A.M., R.R., P.K., T.C., H.L.W., R.G.), Brigham and Women's Hospital; Department of Neurology, Harvard Medical School (B.C.H., C.D.-C., B.I.G., T.C., H.L.W, R.G.), Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital; Biostatistics Center (B.C.H.); Massachusetts General Hospital, Boston, MA; Department of Clinical Neuroscience, Neuroimmunology Unit (M.J., F.P., T.O., M.K.), Karolinska Institute, Stockholm, Sweden; Department of Neurology (S.H., J.O.), School of Medicine, University of California, San Francisco; and Nehme and Therese Tohme Multiple Sclerosis Center (S.J.K.), Faculty of Medicine, American University of Beirut Medical Center, Lebanon
| | - Bonnie I Glanz
- Partners Multiple Sclerosis Center (K.R., B.C.H., A.P., M.A.M., R.R., P.K., T.C., H.L.W., R.G.), Brigham and Women's Hospital; Department of Neurology, Harvard Medical School (B.C.H., C.D.-C., B.I.G., T.C., H.L.W, R.G.), Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital; Biostatistics Center (B.C.H.); Massachusetts General Hospital, Boston, MA; Department of Clinical Neuroscience, Neuroimmunology Unit (M.J., F.P., T.O., M.K.), Karolinska Institute, Stockholm, Sweden; Department of Neurology (S.H., J.O.), School of Medicine, University of California, San Francisco; and Nehme and Therese Tohme Multiple Sclerosis Center (S.J.K.), Faculty of Medicine, American University of Beirut Medical Center, Lebanon
| | - Pia Kivisäkk
- Partners Multiple Sclerosis Center (K.R., B.C.H., A.P., M.A.M., R.R., P.K., T.C., H.L.W., R.G.), Brigham and Women's Hospital; Department of Neurology, Harvard Medical School (B.C.H., C.D.-C., B.I.G., T.C., H.L.W, R.G.), Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital; Biostatistics Center (B.C.H.); Massachusetts General Hospital, Boston, MA; Department of Clinical Neuroscience, Neuroimmunology Unit (M.J., F.P., T.O., M.K.), Karolinska Institute, Stockholm, Sweden; Department of Neurology (S.H., J.O.), School of Medicine, University of California, San Francisco; and Nehme and Therese Tohme Multiple Sclerosis Center (S.J.K.), Faculty of Medicine, American University of Beirut Medical Center, Lebanon
| | - Tanuja Chitnis
- Partners Multiple Sclerosis Center (K.R., B.C.H., A.P., M.A.M., R.R., P.K., T.C., H.L.W., R.G.), Brigham and Women's Hospital; Department of Neurology, Harvard Medical School (B.C.H., C.D.-C., B.I.G., T.C., H.L.W, R.G.), Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital; Biostatistics Center (B.C.H.); Massachusetts General Hospital, Boston, MA; Department of Clinical Neuroscience, Neuroimmunology Unit (M.J., F.P., T.O., M.K.), Karolinska Institute, Stockholm, Sweden; Department of Neurology (S.H., J.O.), School of Medicine, University of California, San Francisco; and Nehme and Therese Tohme Multiple Sclerosis Center (S.J.K.), Faculty of Medicine, American University of Beirut Medical Center, Lebanon
| | - Maja Jagodic
- Partners Multiple Sclerosis Center (K.R., B.C.H., A.P., M.A.M., R.R., P.K., T.C., H.L.W., R.G.), Brigham and Women's Hospital; Department of Neurology, Harvard Medical School (B.C.H., C.D.-C., B.I.G., T.C., H.L.W, R.G.), Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital; Biostatistics Center (B.C.H.); Massachusetts General Hospital, Boston, MA; Department of Clinical Neuroscience, Neuroimmunology Unit (M.J., F.P., T.O., M.K.), Karolinska Institute, Stockholm, Sweden; Department of Neurology (S.H., J.O.), School of Medicine, University of California, San Francisco; and Nehme and Therese Tohme Multiple Sclerosis Center (S.J.K.), Faculty of Medicine, American University of Beirut Medical Center, Lebanon
| | - Fredrik Piehl
- Partners Multiple Sclerosis Center (K.R., B.C.H., A.P., M.A.M., R.R., P.K., T.C., H.L.W., R.G.), Brigham and Women's Hospital; Department of Neurology, Harvard Medical School (B.C.H., C.D.-C., B.I.G., T.C., H.L.W, R.G.), Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital; Biostatistics Center (B.C.H.); Massachusetts General Hospital, Boston, MA; Department of Clinical Neuroscience, Neuroimmunology Unit (M.J., F.P., T.O., M.K.), Karolinska Institute, Stockholm, Sweden; Department of Neurology (S.H., J.O.), School of Medicine, University of California, San Francisco; and Nehme and Therese Tohme Multiple Sclerosis Center (S.J.K.), Faculty of Medicine, American University of Beirut Medical Center, Lebanon
| | - Tomas Olsson
- Partners Multiple Sclerosis Center (K.R., B.C.H., A.P., M.A.M., R.R., P.K., T.C., H.L.W., R.G.), Brigham and Women's Hospital; Department of Neurology, Harvard Medical School (B.C.H., C.D.-C., B.I.G., T.C., H.L.W, R.G.), Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital; Biostatistics Center (B.C.H.); Massachusetts General Hospital, Boston, MA; Department of Clinical Neuroscience, Neuroimmunology Unit (M.J., F.P., T.O., M.K.), Karolinska Institute, Stockholm, Sweden; Department of Neurology (S.H., J.O.), School of Medicine, University of California, San Francisco; and Nehme and Therese Tohme Multiple Sclerosis Center (S.J.K.), Faculty of Medicine, American University of Beirut Medical Center, Lebanon
| | - Mohsen Khademi
- Partners Multiple Sclerosis Center (K.R., B.C.H., A.P., M.A.M., R.R., P.K., T.C., H.L.W., R.G.), Brigham and Women's Hospital; Department of Neurology, Harvard Medical School (B.C.H., C.D.-C., B.I.G., T.C., H.L.W, R.G.), Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital; Biostatistics Center (B.C.H.); Massachusetts General Hospital, Boston, MA; Department of Clinical Neuroscience, Neuroimmunology Unit (M.J., F.P., T.O., M.K.), Karolinska Institute, Stockholm, Sweden; Department of Neurology (S.H., J.O.), School of Medicine, University of California, San Francisco; and Nehme and Therese Tohme Multiple Sclerosis Center (S.J.K.), Faculty of Medicine, American University of Beirut Medical Center, Lebanon
| | - Stephen Hauser
- Partners Multiple Sclerosis Center (K.R., B.C.H., A.P., M.A.M., R.R., P.K., T.C., H.L.W., R.G.), Brigham and Women's Hospital; Department of Neurology, Harvard Medical School (B.C.H., C.D.-C., B.I.G., T.C., H.L.W, R.G.), Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital; Biostatistics Center (B.C.H.); Massachusetts General Hospital, Boston, MA; Department of Clinical Neuroscience, Neuroimmunology Unit (M.J., F.P., T.O., M.K.), Karolinska Institute, Stockholm, Sweden; Department of Neurology (S.H., J.O.), School of Medicine, University of California, San Francisco; and Nehme and Therese Tohme Multiple Sclerosis Center (S.J.K.), Faculty of Medicine, American University of Beirut Medical Center, Lebanon
| | - Jorge Oksenberg
- Partners Multiple Sclerosis Center (K.R., B.C.H., A.P., M.A.M., R.R., P.K., T.C., H.L.W., R.G.), Brigham and Women's Hospital; Department of Neurology, Harvard Medical School (B.C.H., C.D.-C., B.I.G., T.C., H.L.W, R.G.), Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital; Biostatistics Center (B.C.H.); Massachusetts General Hospital, Boston, MA; Department of Clinical Neuroscience, Neuroimmunology Unit (M.J., F.P., T.O., M.K.), Karolinska Institute, Stockholm, Sweden; Department of Neurology (S.H., J.O.), School of Medicine, University of California, San Francisco; and Nehme and Therese Tohme Multiple Sclerosis Center (S.J.K.), Faculty of Medicine, American University of Beirut Medical Center, Lebanon
| | - Samia J Khoury
- Partners Multiple Sclerosis Center (K.R., B.C.H., A.P., M.A.M., R.R., P.K., T.C., H.L.W., R.G.), Brigham and Women's Hospital; Department of Neurology, Harvard Medical School (B.C.H., C.D.-C., B.I.G., T.C., H.L.W, R.G.), Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital; Biostatistics Center (B.C.H.); Massachusetts General Hospital, Boston, MA; Department of Clinical Neuroscience, Neuroimmunology Unit (M.J., F.P., T.O., M.K.), Karolinska Institute, Stockholm, Sweden; Department of Neurology (S.H., J.O.), School of Medicine, University of California, San Francisco; and Nehme and Therese Tohme Multiple Sclerosis Center (S.J.K.), Faculty of Medicine, American University of Beirut Medical Center, Lebanon
| | - Howard L Weiner
- Partners Multiple Sclerosis Center (K.R., B.C.H., A.P., M.A.M., R.R., P.K., T.C., H.L.W., R.G.), Brigham and Women's Hospital; Department of Neurology, Harvard Medical School (B.C.H., C.D.-C., B.I.G., T.C., H.L.W, R.G.), Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital; Biostatistics Center (B.C.H.); Massachusetts General Hospital, Boston, MA; Department of Clinical Neuroscience, Neuroimmunology Unit (M.J., F.P., T.O., M.K.), Karolinska Institute, Stockholm, Sweden; Department of Neurology (S.H., J.O.), School of Medicine, University of California, San Francisco; and Nehme and Therese Tohme Multiple Sclerosis Center (S.J.K.), Faculty of Medicine, American University of Beirut Medical Center, Lebanon
| | - Roopali Gandhi
- Partners Multiple Sclerosis Center (K.R., B.C.H., A.P., M.A.M., R.R., P.K., T.C., H.L.W., R.G.), Brigham and Women's Hospital; Department of Neurology, Harvard Medical School (B.C.H., C.D.-C., B.I.G., T.C., H.L.W, R.G.), Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital; Biostatistics Center (B.C.H.); Massachusetts General Hospital, Boston, MA; Department of Clinical Neuroscience, Neuroimmunology Unit (M.J., F.P., T.O., M.K.), Karolinska Institute, Stockholm, Sweden; Department of Neurology (S.H., J.O.), School of Medicine, University of California, San Francisco; and Nehme and Therese Tohme Multiple Sclerosis Center (S.J.K.), Faculty of Medicine, American University of Beirut Medical Center, Lebanon
| |
Collapse
|